Abemaciclib, ribociclib, and palbociclib are all CDK4/6 inhibitors that are currently approved in the United States and have been shown to improve the clinical outcomes for patients with breast cancer when combined with endocrine therapy [5]. Here, CDK4 is linked to breast cancer.